Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
1. Novo Nordisk reports promising early results for amycretin weight-loss drug. 2. Subjects in trial lost up to 22% body weight at high dosage. 3. Stock surged 9% after the announcement, following recent declines. 4. Strong results could enhance Novo Nordisk's position in a competitive market. 5. Company plans further clinical development due to encouraging trial outcomes.